Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …

Background Age is a major risk factor for venous thromboembolism (VTE), yet patients
aged≥ 90 years are under‐represented in clinical trials of anticoagulant therapy. The …

Background Safety data for different anticoagulant medications in venous thromboembolism
(VTE) are scarce, in particular for extended treatment. Objectives To compare major …

High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after
percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs …

Simple Summary Venous thromboembolism (VTE) is a common and often fatal complication
in cancer patients. The initial treatment for VTE in cancer patients is typically low molecular …

When used in fixed doses for the treatment of venous thromboembolism (VTE) in patients
with or without cancer, direct oral anticoagulants (DOACs) have improved risk–benefit …

Background: Direct oral anticoagulants (DOACs), including edoxaban, rivaroxaban, and
apixaban, are administered for the treatment of venous thromboembolism (VTE) in Japan …

Background Given the evolving application and promising outcomes of direct oral
anticoagulants (DOACs) in various thromboembolic conditions, we aimed to compare the …